AU624917B2 - Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder - Google Patents

Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Info

Publication number
AU624917B2
AU624917B2 AU50734/90A AU5073490A AU624917B2 AU 624917 B2 AU624917 B2 AU 624917B2 AU 50734/90 A AU50734/90 A AU 50734/90A AU 5073490 A AU5073490 A AU 5073490A AU 624917 B2 AU624917 B2 AU 624917B2
Authority
AU
Australia
Prior art keywords
cycloserine
alanine
memory
treatment
cognitive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU50734/90A
Other languages
English (en)
Other versions
AU5073490A (en
Inventor
Alexis A. Cordi
Michel R. Jans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of AU5073490A publication Critical patent/AU5073490A/en
Application granted granted Critical
Publication of AU624917B2 publication Critical patent/AU624917B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Detergent Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
AU50734/90A 1989-03-15 1990-03-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder Ceased AU624917B2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US32427989A 1989-03-15 1989-03-15
US324279 1989-03-15
US07/473,241 US5061721A (en) 1989-03-15 1990-02-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US473241 1990-02-06

Publications (2)

Publication Number Publication Date
AU5073490A AU5073490A (en) 1990-09-20
AU624917B2 true AU624917B2 (en) 1992-06-25

Family

ID=26984373

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50734/90A Ceased AU624917B2 (en) 1989-03-15 1990-03-06 Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder

Country Status (17)

Country Link
US (1) US5061721A (https=)
EP (1) EP0387867B1 (https=)
JP (1) JP2963720B2 (https=)
KR (1) KR900013961A (https=)
AT (1) ATE88890T1 (https=)
AU (1) AU624917B2 (https=)
CA (1) CA2010635C (https=)
DE (1) DE69001503T2 (https=)
DK (1) DK0387867T3 (https=)
ES (1) ES2055197T3 (https=)
FI (1) FI901289A7 (https=)
GR (1) GR3008225T3 (https=)
IE (1) IE64130B1 (https=)
IL (1) IL93562A (https=)
NO (1) NO901198L (https=)
NZ (1) NZ232809A (https=)
PT (1) PT93424B (https=)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153193A (en) * 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5302609A (en) * 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US20040208875A1 (en) 1995-03-15 2004-10-21 Queen's University At Kingston Method for treating amyloidosis
DE69434571T2 (de) * 1993-03-29 2006-08-03 Queen's University At Kingston, Kingston Propan-1,3-disulphonsäure und deren pharmazeutisch akzeptable Salze zur Behandlung von Amyloidosis
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
WO1996015788A1 (en) * 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
US5731348A (en) * 1995-02-15 1998-03-24 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
US6515103B1 (en) 1996-07-22 2003-02-04 University Of Utah Research Foundation Conantokins
EP0964691A4 (en) 1996-07-22 2002-10-30 Cognetix Inc USE OF CONANTOKINE
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
DE1073432T1 (de) * 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
US6551993B1 (en) * 1999-08-16 2003-04-22 Thomas Jefferson University Partial agonists at the glycine modulatory site of the NMDA receptor for treating cognitive dysfunction
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20050096396A1 (en) * 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1389181A4 (en) 2001-04-02 2005-10-19 Panorama Res Inc NITROXIDE AND NITRONE ANTIOXIDANTS AS THERAPEUTICS
US20040235889A1 (en) * 2001-05-02 2004-11-25 Miao-Kun Sun Carbonic anhydrase activator for enhancing learning and memory
CA2478808A1 (en) * 2002-03-15 2003-09-25 H. Lundbeck A/S Use of asc-1 inhibitors to treat neurological and psychiatric disorders
EP2260844A1 (en) 2003-05-27 2010-12-15 Merz Pharma GmbH & Co. KGaA Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
US7244764B2 (en) 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
WO2005065308A2 (en) 2003-12-29 2005-07-21 Jason Mcdevitt Compositions and methods to treat recurrent medical conditions
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
WO2006085149A2 (en) 2004-12-22 2006-08-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
JP5666087B2 (ja) 2005-04-06 2015-02-12 アダマス・ファーマシューティカルズ・インコーポレーテッド Ｃｎｓ関連疾患の治療のための方法及び組成物
TW200716088A (en) 2005-04-15 2007-05-01 Neurochem Int Ltd Formulations and methods for treating amyloidosis
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
WO2008124814A2 (en) * 2007-04-10 2008-10-16 Mcdevitt Jason P Sublingual formulations of d-cycloserine and methods of using same
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
TWI544923B (zh) * 2009-12-29 2016-08-11 何應瑞 用於治療神經退化性疾病之醫藥組合物
CN105037492A (zh) 2010-02-11 2015-11-11 西北大学 二级结构稳定化的nmda受体调节剂及其用途
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
JP5689026B2 (ja) * 2010-06-17 2015-03-25 株式会社 資生堂 水中油型乳化皮膚化粧料
US9789093B2 (en) * 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
EP2931291B1 (en) 2012-12-11 2021-10-20 The McLean Hospital Corporation Xenon treatment as an adjunct to psychotherapy for psychiatric disorders
KR20150110586A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
EA032649B1 (ru) 2013-01-29 2019-06-28 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
SG11201505942YA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
SG11201505862TA (en) 2013-01-29 2015-08-28 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
KR20150110787A (ko) 2013-01-29 2015-10-02 노렉스, 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
BR112018073663A2 (pt) 2016-05-19 2019-04-30 Aptinyx Inc. moduladores de receptores nmda spiro-lactâmicos e seus usos
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
SG10202101055VA (en) 2016-08-01 2021-03-30 Aptinyx Inc Spiro-lactam nmda receptor modulators and uses thereof
MX385336B (es) 2016-08-01 2025-03-18 Aptinyx Inc Moduladores del receptor nmda espiro-lactam y uso de los mismos.
EP3490994B8 (en) 2016-08-01 2024-03-13 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
WO2018026782A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2019527232A (ja) 2016-08-01 2019-09-26 アプティニックス インコーポレイテッド スピロ−ラクタムｎｍｄａ修飾因子及びこれを用いた方法
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
CN112204031B (zh) 2018-01-31 2024-05-24 元羿生物科技(香港)有限公司 螺-内酰胺nmda受体调节剂及其用途
WO2020252384A1 (en) * 2019-06-14 2020-12-17 Vorsanger Gary Treatment methods utilizing oxytocin receptor agonists
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
JP7541765B2 (ja) * 2019-11-27 2024-08-29 諾羅瑞韋株式会社 うつ病を治療するためのシクロセリン及びリチウム併用療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
AU2631988A (en) * 1987-12-01 1989-06-01 G.D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3428730A (en) * 1967-06-30 1969-02-18 Hamao Umezawa Antibacterial mixture of o-carbamyl-d-serine and d-4-amino-3-isoxazolidone

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031231A (en) * 1974-06-13 1977-06-21 Merck & Co., Inc. Antibacterial composition comprising 3-fluoro-D-alanine or deutero analog in combination with auto-antagonist inhibitor
AU2631988A (en) * 1987-12-01 1989-06-01 G.D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers
US4904681A (en) * 1987-12-01 1990-02-27 G. D. Searle & Co. D-cycloserine and its prodrugs as cognitive enhancers

Also Published As

Publication number Publication date
EP0387867B1 (en) 1993-05-05
PT93424A (pt) 1990-11-07
IL93562A (en) 1996-01-31
GR3008225T3 (https=) 1993-09-30
IL93562A0 (en) 1990-11-29
IE64130B1 (en) 1995-07-12
AU5073490A (en) 1990-09-20
ES2055197T3 (es) 1994-08-16
CA2010635A1 (en) 1990-09-15
DK0387867T3 (da) 1993-06-01
PT93424B (pt) 1996-08-30
DE69001503T2 (de) 1993-09-09
ATE88890T1 (de) 1993-05-15
KR900013961A (ko) 1990-10-22
NZ232809A (en) 1992-05-26
JPH03148221A (ja) 1991-06-25
FI901289A7 (fi) 1990-09-16
JP2963720B2 (ja) 1999-10-18
NO901198L (no) 1990-09-17
CA2010635C (en) 2001-03-06
EP0387867A1 (en) 1990-09-19
US5061721A (en) 1991-10-29
NO901198D0 (no) 1990-03-14
DE69001503D1 (de) 1993-06-09
IE900921L (en) 1990-09-15
FI901289A0 (fi) 1990-03-15

Similar Documents

Publication Publication Date Title
AU624917B2 (en) Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
AU2813089A (en) Use of a glycine b partial agonist for memory and learning enhancement or treatment of a cognitive disorder
AU5232996A (en) Schizophrenia
EP0633017A3 (de) Kosmetische und dermatologische Zubereitungen mit einem Gehalt an Delta-Aminolävulinsäure.
AU1165588A (en) Knurled cup-point set screw
GR3023817T3 (en) BIS-STAUROSPORINE AND K-252a DERIVATIVES.
AU4717189A (en) Low volatility amine salts of pesticides
GR3005624T3 (https=)
EP0657512A3 (en) Silicone containing artists' media
GR3031149T3 (en) Process for the manufacture of (s)-3-amino-1-substituted-pyrrolidines.
AU609637B2 (en) Process for the treatment of effluents containing cyanide and/or other oxidizable substances
AU2158688A (en) Use of bezafibrate for treating diabetes
NO157403C (no) Middel for behandling av saar.
HU900822D0 (en) Trichoderma-fungus and fungicid containing it
USD355861S (en) Electronic voltage tester instrument
AU3689193A (en) Method of treating osteoporosis with 1 alpha, 24 (R)-dihydroxy-22 (E)-dehydro-vitamin D3
GR3018651T3 (en) Treatment of ocular hypertention with a synergistic combination
GB2241550B (en) Fastener
EP0410430A3 (en) Process for the microbiological discontinual preparation of l-carnitine
AU7375994A (en) Treatment of cyanides in effluents with caro's acid
ATE186746T1 (de) Neue anwendung von alcaligenes faecalis penicillin g acylase
AU613510B2 (en) Use of zofenopril for the treatment of rheumatoid arthritis
ZA901995B (en) Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
EP0092386A3 (en) Hydantoin therapeutic agents
AU6217694A (en) Use of triazine compounds for the treatment of memory and learning disorders